Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received an average rating of “Hold” from the fifteen ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $53.50.

A number of equities analysts recently weighed in on IART shares. Jefferies Group reissued a “buy” rating and issued a $56.00 price target on shares of Integra LifeSciences in a research note on Sunday, October 29th. Zacks Investment Research raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Tuesday, October 10th. Oppenheimer reaffirmed a “buy” rating and set a $60.00 target price on shares of Integra LifeSciences in a research note on Monday, September 18th. UBS reaffirmed a “buy” rating and set a $57.00 target price on shares of Integra LifeSciences in a research note on Tuesday, October 31st. Finally, TheStreet cut Integra LifeSciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th.

In other news, VP Richard D. Gorelick sold 1,500 shares of Integra LifeSciences stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total transaction of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Barbara B. Hill purchased 10,768 shares of Integra LifeSciences stock in a transaction dated Tuesday, October 31st. The shares were purchased at an average price of $46.66 per share, with a total value of $502,434.88. Following the completion of the acquisition, the director now owns 55,540 shares in the company, valued at $2,591,496.40. The disclosure for this purchase can be found here. Insiders own 21.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its holdings in Integra LifeSciences by 213.1% in the 3rd quarter. GSA Capital Partners LLP now owns 28,249 shares of the life sciences company’s stock worth $1,426,000 after purchasing an additional 19,226 shares during the last quarter. California Public Employees Retirement System lifted its holdings in Integra LifeSciences by 6.8% in the 3rd quarter. California Public Employees Retirement System now owns 132,002 shares of the life sciences company’s stock worth $6,663,000 after purchasing an additional 8,402 shares during the last quarter. Zions Bancorporation acquired a new stake in Integra LifeSciences in the 3rd quarter worth approximately $205,000. Orbimed Advisors LLC lifted its holdings in Integra LifeSciences by 155.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock worth $55,069,000 after purchasing an additional 664,000 shares during the last quarter. Finally, Segall Bryant & Hamill LLC lifted its holdings in Integra LifeSciences by 20.9% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 112,520 shares of the life sciences company’s stock worth $5,680,000 after purchasing an additional 19,486 shares during the last quarter. Institutional investors and hedge funds own 87.62% of the company’s stock.

Shares of Integra LifeSciences (NASDAQ:IART) traded up $0.99 on Thursday, reaching $50.01. The company had a trading volume of 675,200 shares, compared to its average volume of 594,125. The stock has a market cap of $3,846.96, a PE ratio of 27.08, a P/E/G ratio of 2.16 and a beta of 0.65. Integra LifeSciences has a 1 year low of $40.51 and a 1 year high of $56.42. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). The company had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. Integra LifeSciences had a return on equity of 16.35% and a net margin of 4.52%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 EPS. equities analysts anticipate that Integra LifeSciences will post 1.84 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Given Average Rating of “Hold” by Brokerages” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/14/integra-lifesciences-holdings-corporation-iart-given-average-rating-of-hold-by-brokerages.html.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.